---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-086131"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T03:51:27.202464+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protagonist Q2 net loss $41M; rusfertide Phase 3 enrollment slower, cash runway to end 2024

## Summary
- Net loss of $41.0M ($0.84 per share) vs $30.8M loss in Q2 2021; license revenue $0.9M.
- Cash and equivalents $291.9M, expected to fund operations through end of 2024.
- Phase 3 VERIFY study enrollment slower than anticipated; target to complete enrollment by end of first half 2023.
- Janssen (PN-235) advancing Phase 2b psoriasis studies; $10M milestone for second indication Phase 2 start, $50M for Phase 3 dosing.
- PN-943 seeking FDA guidance for Phase 3 and partnership; IDEAL study results to be presented at UEGW Oct 2022.

## SEC filing metadata
- accession: 0001104659-22-086131
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465922086131/0001104659-22-086131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465922086131/tm2222452d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-086131
- JSON: https://secwatch.observer/filing/0001104659-22-086131.json
- Plain text: https://secwatch.observer/filing/0001104659-22-086131.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.